middle.news
Argenica Clears Key FDA Genotoxicity Test, Paving Way for Phase 2b Trial
9:01am on Thursday 21st of May, 2026 AEST
•
Healthcare
Read Story
Argenica Clears Key FDA Genotoxicity Test, Paving Way for Phase 2b Trial
9:01am on Thursday 21st of May, 2026 AEST
Key Points
ARG-007 shows no genotoxicity in FDA-requested Mouse Lymphoma Assay
Two of three FDA safety assays complete; hERG cardiac assay underway
Completion of assays needed to lift FDA clinical hold on IND
Phase 2b stroke trial preparations progressing in US and Australia
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE